Biomoda Inc. (BMOD.OB) Inks Deal with Obio to Support Cancer Detection Research and Development
Cancer diagnostics company Biomoda Inc. today announced it has signed an agreement with Obio, a corporation formed to pursue public and private funding for cancer research, to establish a CLIA-certified Biomoda clinical laboratory in Ohio to fuel ongoing research and development of Biomoda's porphyrin-based assay for the detection of early-stage cancer. Clinical Laboratory Improvement Amendments (CLIA) were implemented by Congress in 1988 and certified by the Department of Health and Human Services to set boundaries and regulations for laboratory testing to ensure accuracy and reliability of patient test results. For Biomoda, the agreement will strengthen its partnership with Obio and…